Brief: Cytodyn Announces Clinically Significant Top-Line Results From Phase 2 Trial In Mild-To-Moderate Covid-19 Patients

Cytodyn

11/08/2020 14:23

Aug 11 (Reuters) - Cytodyn Inc  CYDY.PK :
    * CYTODYN ANNOUNCES CLINICALLY SIGNIFICANT TOP-LINE RESULTS
FROM
ITS PHASE 2 TRIAL IN MILD-TO-MODERATE COVID-19 PATIENTS
    * CYTODYN ANNOUNCES CLINICALLY SIGNIFICANT TOP-LINE RESULTS
FROM
ITS PHASE 2 TRIAL IN MILD-TO-MODERATE COVID-19 PATIENTS
    * CYTODYN INC - PRIMARY ENDPOINT SHOWS EARLY CLINICAL
IMPROVEMENT
IN SYMPTOM SCORE AT DAY 3 IN PATIENTS RECEIVING LERONLIMAB
    * CYTODYN INC - LERONLIMAB ALSO DEMONSTRATED STATISTICALLY
SIGNIFICANT IMPROVEMENT VERSUS PLACEBO IN KEY SECONDARY EFFICACY
ENDPOINT, NEWS2
    * CYTODYN INC - RESULTS WILL BE REPORTED TO UNITED STATES
FDA,
UNITED KINGDOM MHRA, AND EUROPEAN UNION REGULATORY AGENCY, EMA

Source text for Eikon:  ID:nGNXbyj9kz 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))